Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Innocent Mushi

Doris Riether

Monika Ermann

Eugene R Hickey

David S Thomson

Angela Kay Berry

Nigel James Blumire

Renee M Zindell

Pier Francesco Cirillo

Alessandra Bartolozzi

James Edward Jenkins

Christopher Francis Palmer

Patricia Amouzegh

Lifen Wu

Achim Sauer

Stephen East

Someina Khor

Malcolm Taylor

Markus Ostermeier

Robert John Scott

Stephen Peter East

Eugene Richard Hickey

Chandana Parke

Chandana Chowdhury

David Smith Thomson

Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain. 

Compounds which modulate the CB2 receptor

Compounds which modulate the CB2 receptor are disclosed. The compounds are useful for treating CB2 receptor-mediated diseases such as pain.

Amine and ether compounds which modulate the CB2 receptor

Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

Compounds which selectively modulate the CB2 receptor

Therapeutic uses of compounds which selectively modulate the CB2 receptor

are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

Compound of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

Compounds are provided which bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, the compounds having the general formula wherein, R, R, A, Y, X, Arand Arhave the meanings given in the specification, and the preparation and use thereof. The compounds are valuable CB2 receptor modulators.

Growing community of inventors

Didcot, United Kingdom

Innocent Mushi